170 related articles for article (PubMed ID: 20816930)
21. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle.
Han M; Diao YY; Jiang HL; Ying XY; Chen DW; Liang WQ; Gao JQ
Int J Pharm; 2011 Nov; 420(2):404-11. PubMed ID: 21945184
[TBL] [Abstract][Full Text] [Related]
22. Fabrication of psoralen-loaded lipid-polymer hybrid nanoparticles and their reversal effect on drug resistance of cancer cells.
Yuan Y; Chiba P; Cai T; Callaghan R; Bai L; Cole SPC; Cai Y
Oncol Rep; 2018 Aug; 40(2):1055-1063. PubMed ID: 29901161
[TBL] [Abstract][Full Text] [Related]
23. Theranostic Nanoprobe Mediated Simultaneous Monitoring and Inhibition of P-Glycoprotein Potentiating Multidrug-Resistant Cancer Therapy.
Wei Y; Xia H; Zhang F; Wang K; Luo P; Wu Y; Liu S
Anal Chem; 2019 Sep; 91(17):11200-11208. PubMed ID: 31403276
[TBL] [Abstract][Full Text] [Related]
24. Fabrication of doxorubicin nanoparticles by controlled antisolvent precipitation for enhanced intracellular delivery.
Tam YT; To KK; Chow AH
Colloids Surf B Biointerfaces; 2016 Mar; 139():249-58. PubMed ID: 26724466
[TBL] [Abstract][Full Text] [Related]
25. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance.
Su X; Song H; Niu F; Yang K; Kou G; Wang X; Chen H; Li W; Guo S; Li J; Li B; Feng SS; Jiang J; Yin C; Gao J
Nanomedicine (Lond); 2015; 10(13):2033-50. PubMed ID: 26084553
[TBL] [Abstract][Full Text] [Related]
26. Reversal of P-glycoprotein-mediated multidrug resistance by doxorubicin and quinine co-loaded liposomes in tumor cells.
Shen Q; Qiu L
J Liposome Res; 2017 Dec; 27(4):293-301. PubMed ID: 27581212
[TBL] [Abstract][Full Text] [Related]
27. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance.
Lu J; Zhao W; Liu H; Marquez R; Huang Y; Zhang Y; Li J; Xie W; Venkataramanan R; Xu L; Li S
J Control Release; 2014 Dec; 196():272-86. PubMed ID: 25456831
[TBL] [Abstract][Full Text] [Related]
28. DOX-loaded peptide dendritic copolymer nanoparticles for combating multidrug resistance by regulating the lysosomal pathway of apoptosis in breast cancer cells.
Wang J; Li N; Cao L; Gao C; Zhang Y; Shuai Q; Xie J; Luo K; Yang J; Gu Z
J Mater Chem B; 2020 Feb; 8(6):1157-1170. PubMed ID: 31951231
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin and curcumin co-delivery by lipid nanoparticles for enhanced treatment of diethylnitrosamine-induced hepatocellular carcinoma in mice.
Zhao X; Chen Q; Li Y; Tang H; Liu W; Yang X
Eur J Pharm Biopharm; 2015 Jun; 93():27-36. PubMed ID: 25770771
[TBL] [Abstract][Full Text] [Related]
30. Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin.
Subedi RK; Kang KW; Choi HK
Eur J Pharm Sci; 2009 Jun; 37(3-4):508-13. PubMed ID: 19406231
[TBL] [Abstract][Full Text] [Related]
31. Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.
Wang C; Sun X; Wang K; Wang Y; Yang F; Wang H
Drug Deliv; 2016 Oct; 23(8):2697-2702. PubMed ID: 26203692
[TBL] [Abstract][Full Text] [Related]
32. Ceramide and N,N,N-Trimethylphytosphingosine-Iodide (TMP-I)-Based Lipid Nanoparticles for Cancer Therapy.
Balakrishnan P; Song CK; Jahn A; Cho HJ
Pharm Res; 2016 Jan; 33(1):206-16. PubMed ID: 26337769
[TBL] [Abstract][Full Text] [Related]
33. Sodium alginate-cross-linked polymyxin B sulphate-loaded solid lipid nanoparticles: Antibiotic resistance tests and HaCat and NIH/3T3 cell viability studies.
Severino P; Chaud MV; Shimojo A; Antonini D; Lancelloti M; Santana MH; Souto EB
Colloids Surf B Biointerfaces; 2015 May; 129():191-7. PubMed ID: 25863712
[TBL] [Abstract][Full Text] [Related]
34. A telomerase-responsive nanoprobe with theranostic properties in tumor cells.
Zhang HH; Zhao LD; Zuo P; Yin BC; Ye BC
Talanta; 2020 Aug; 215():120898. PubMed ID: 32312443
[TBL] [Abstract][Full Text] [Related]
35. [Study on preparation and characterization of resveratrol solid lipid nanoparticles and its anticancer effects in vitro].
Zhang QH; Xiong QP; Shi YY; Zhang DY
Zhong Yao Cai; 2010 Dec; 33(12):1929-32. PubMed ID: 21548373
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
[No Abstract] [Full Text] [Related]
37. Psoralen-loaded lipid-polymer hybrid nanoparticles enhance doxorubicin efficacy in multidrug-resistant HepG2 cells.
Yuan Y; Cai T; Callaghan R; Li Q; Huang Y; Wang B; Huang Q; Du M; Ma Q; Chiba P; Cai Y
Int J Nanomedicine; 2019; 14():2207-2218. PubMed ID: 30988617
[TBL] [Abstract][Full Text] [Related]
38. Cell deformation and acquired drug resistance: elucidating the major influence of drug-nanocarrier delivery systems.
Nandi S; Kale NR; Takale V; Chate GC; Bhave M; Banerjee SS; Khandare JJ
J Mater Chem B; 2020 Mar; 8(9):1852-1862. PubMed ID: 32022091
[TBL] [Abstract][Full Text] [Related]
39. Co-delivery of plasmid DNA and doxorubicin by solid lipid nanoparticles for lung cancer therapy.
Han Y; Zhang P; Chen Y; Sun J; Kong F
Int J Mol Med; 2014 Jul; 34(1):191-6. PubMed ID: 24804644
[TBL] [Abstract][Full Text] [Related]
40. Improved Cytotoxic Effect of Doxorubicin by Its Combination with Sclareol in Solid Lipid Nanoparticle Suspension.
Oliveira MS; Lima BHS; Goulart GAC; Mussi SV; Borges GSM; Oréfice RL; Ferreira LAM
J Nanosci Nanotechnol; 2018 Aug; 18(8):5609-5616. PubMed ID: 29458616
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
